2,4-Dimethoxybenzeneboronic acid | CAS:133730-34-4

We serve 2,4-Dimethoxybenzeneboronic acid CAS:133730-34-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2,4-Dimethoxybenzeneboronic acid

Product Name: 2,4-Dimethoxybenzeneboronic acid
Other Name:
2,4-Dimethoxybenzeneboronic acid
2,4-Dimethoxyphenylboronic Acid
(2,4-dimethoxyphenyl)boronic acid
CAS No: 133730-34-4
MF: C8H11BO4
MW: 181.98200
Density: 1.19g/cm3
Boiling point: 361.1ºC at 760mmHg
Melting point: 125-127 °C(lit.)
Flash point: 172.2ºC
Refractive index: 1.517
UN Number: Not dangerous goods.
UN Proper Shipping Name: ENot dangerous goods.
Transport hazard class: Not dangerous goods.
Packing group: Not dangerous goods.
 
Specification
Appearance: White powder
Assay: ≥98.0%
Water: ≤0.50%
 
Application
Be used as pharmaceutical intermediate.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.



Contact us for information like 2,4-Dimethoxybenzeneboronic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2,4-dimethoxyphenyl)boronic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,4-Dimethoxybenzeneboronic acid Use and application,2,4-Dimethoxyphenylboronic Acid technical grade,usp/ep/jp grade.


Related News: ICIG companies currently employ more than 3,000 people and operate 15 manufacturing facilities in Europe and the United States.6-Fluoronicotinic acid manufacturer 2,7-Dibromo-9-(4-bromophenyl)-9H-carbazole supplier Slower growth in pesticide intermediates weighed on industrial business. In the first three quarters, the company’s operating income was 2.977 billion yuan, a year-on-year increase of 2.57%.(S)-4-Methyloxazolidine-2,5-dione vendor We have leading expertise in strategy and operational implementation of pre-approval access programs making pharmaceutical products under clinical development available for patients and Inceptua’s clinical trial services business offers high quality clinical comparator sourcing and manufacturing services with an agile global supply chain to ensure that products are delivered exactly when needed.They have also voiced frustrations about patients from mainland China hiding their travel and medical history, potentially endangering other patients.